Torna al Registre Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorSimon, Maria S.
dc.contributor.authorBurger, Bianka
dc.contributor.authorWeidinger, Elif
dc.contributor.authorArteaga Henriquez, Gara
dc.contributor.authorZill, Peter
dc.contributor.authorMusil, Richard
dc.date.accessioned2022-05-05T07:43:57Z
dc.date.available2022-05-05T07:43:57Z
dc.date.issued2021-09-27
dc.identifier.citationSimon MS, Burger B, Weidinger E, Arteaga-Henríquez G, Zill P, Musil R, et al. Efficacy of Sertraline Plus Placebo or Add-On Celecoxib in Major Depressive Disorder: Macrophage Migration Inhibitory Factor as a Promising Biomarker for Remission After Sertraline-Results From a Randomized Controlled Clinical Trial. Front Psychiatry. 2021 Sep 27;12:615261.
dc.identifier.issn2048-8513
dc.identifier.urihttps://hdl.handle.net/11351/7480
dc.descriptionTrastorn depressiu major; Tractament antiinflamatori; Citocina
dc.description.sponsorshipThis present work was funded by the EU 7th Framework program (grant number EU-FP7-CP-IP-2008-222963/EU-FP7-PEOPLE-2009-IAPP-MarieCurie-286334) and Horizon 2020 (grant number H2020-SC1-2016-2017/H2020-SC1-2017-Two-Stage-RTD). Further, part of this work was supported by the foundation Immunität und Seele. The funders had no role in the study design, data collection and analysis, or decision to publish.
dc.language.isoeng
dc.publisherFrontiers Media
dc.relation.ispartofseriesFrontiers in Psychiatry;12
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectMalalties mentals - Tractament
dc.subjectDepressius
dc.subjectAntiinflamatoris
dc.subject.meshDepressive Disorder, Major
dc.subject.mesh/drug therapy
dc.subject.meshDrug Therapy, Combination
dc.subject.meshAnti-Inflammatory Agents
dc.titleEfficacy of Sertraline Plus Placebo or Add-On Celecoxib in Major Depressive Disorder: Macrophage Migration Inhibitory Factor as a Promising Biomarker for Remission After Sertraline-Results From a Randomized Controlled Clinical Trial
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3389/fpsyt.2021.615261
dc.subject.decstrastorno depresivo mayor
dc.subject.decs/farmacoterapia
dc.subject.decsfarmacoterapia combinada
dc.subject.decsantiinflamatorios
dc.relation.publishversionhttps://doi.org/10.3389/fpsyt.2021.615261
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Simon MS, Weidinger E, Zill P, Musil R] Department of Psychiatry and Psychotherapy, University Hospital, Ludwig-Maximilians-University, Munich, Germany. [Burger B] Marion von Tessin Memory-Center, Munich, Germany. [Arteaga-Henríquez G] Servei de Psiquiatria, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain
dc.identifier.pmid34646168
dc.identifier.wos000736068200011
dc.relation.projectidinfo:eu-repo/grantAgreement/EC/FP7/286334
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Thumbnail
Thumbnail

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple